SCHEMBL26106331

SCHEMBL26106331

O=Cc1cc(Cl)nc2[nH]ccc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
AXL P30530 2/20 0.37
PRKCI P41743 2/20 0.37
KMT2A Q03164 2/20 0.37
CDK8 P49336 1/20 0.33
CYP2A6 P11509 2/20 0.33
TDP1 Q9NUW8 1/20 0.32
ATR Q13535 5/20 0.32
ATRIP Q8WXE1 5/20 0.32
CHEK1 O14757 1/20 0.32
PDCD1 Q15116 1/20 0.32
CD274 Q9NZQ7 1/20 0.32
NUDT1 P36639 1/20 0.32
CCNT1 O60563 1/20 0.32
CDK9 P50750 1/20 0.32
HASPIN Q8TF76 1/20 0.32
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30611953 1.00 DYRK1A (0.38) DYRK1AADORA2AADORA1AXLPRKCI
SCHEMBL29957561 0.79 DYRK1A (0.38) DYRK1AADORA2AADORA1KMT2ACDK8
SCHEMBL23147958 0.77 TGFBR1 (0.41) DYRK1AADORA2AADORA1AXLPRKCI
SCHEMBL29721930 0.77 TGFBR1 (0.41) DYRK1AADORA2AADORA1AXLPRKCI
SCHEMBL20651528 0.77 AXL (0.49) DYRK1AADORA2AADORA1AXLPRKCI
SCHEMBL13906236 0.76 PRKCI (0.52) DYRK1AADORA2AADORA1AXLPRKCI
SCHEMBL31275227 0.76 PRKCI (0.52) DYRK1AADORA2AADORA1AXLPRKCI
SCHEMBL29954439 0.76 ALDH1A1 (0.38) DYRK1AADORA2AADORA1KMT2AATR
SCHEMBL29956462 0.74 MAPK1 (0.42) DYRK1AADORA2AADORA1AXLKMT2A
SCHEMBL1714533 0.74 KMT2A (0.53) ADORA2AADORA1KMT2ACYP2A6CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214991-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS 2025-07-03 US disclosed
EP-4499629-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) 2025-02-05 EP disclosed
WO-2023183919-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) 2023-09-28 WO disclosed
WO-2023183919-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) 2023-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214991-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS IKZF1, IKZF2, IKZF3 DYRK1A 1004/4885ADORA2A 4579/4885ADORA1 4798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.